Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO-Reference-Cited by-同舟云学术

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

Published:2020-12-07 Issue:6 Volume:87 Page:2511-2520
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Gibiansky Ekaterina¹,Petry Claire²,Mercier Francois²,Günther Andreas²,Herman Ann³,Kappos Ludwig⁴,Hauser Stephen⁵,Yamamoto Yumi²,Wang Qing²,Model Fabian²,Kletzl Heidemarie²^ORCID

Affiliation:

1. QuantPharm LLC MD USA

2. F. Hoffmann‐La Roche Innovation Center Basel Switzerland

3. Genentech South San Francisco CA USA

4. University Hospital Basel Basel Switzerland

5. University of California San Francisco CA USA

Funder

Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14658

Reference27 articles.

1. Multiple sclerosis

2. Multiple Sclerosis

3. Silent progression in disease activity–free relapsing multiple sclerosis

4. Multiple Sclerosis

5. Primary-progressive multiple sclerosis

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

2. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11

3. Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study;BMJ Neurology Open;2024-06

4. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma;Clinical and Translational Science;2024-05-29

5. Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study;Journal of Central Nervous System Disease;2024-05-05